Tianjin Pharmaceutical Da Ren Tang Group Corp Ltd banner

Tianjin Pharmaceutical Da Ren Tang Group Corp Ltd
SSE:600329

Watchlist Manager
Tianjin Pharmaceutical Da Ren Tang Group Corp Ltd Logo
Tianjin Pharmaceutical Da Ren Tang Group Corp Ltd
SSE:600329
Watchlist
Price: 39.96 CNY 0.18%
Market Cap: ¥30.8B

Tianjin Pharmaceutical Da Ren Tang Group Corp Ltd
Net Income (Common)

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
TTM
|
See Also

Tianjin Pharmaceutical Da Ren Tang Group Corp Ltd
Net Income (Common) Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Net Income (Common) CAGR 3Y CAGR 5Y CAGR 10Y
Tianjin Pharmaceutical Da Ren Tang Group Corp Ltd
SSE:600329
Net Income (Common)
¥2.1B
CAGR 3-Years
35%
CAGR 5-Years
26%
CAGR 10-Years
17%
H
Hansoh Pharmaceutical Group Company Ltd
HKEX:3692
Net Income (Common)
¥5.6B
CAGR 3-Years
29%
CAGR 5-Years
17%
CAGR 10-Years
N/A
Jiangsu Hengrui Pharmaceuticals Co Ltd
SSE:600276
Net Income (Common)
¥8.1B
CAGR 3-Years
28%
CAGR 5-Years
5%
CAGR 10-Years
13%
Yunnan Baiyao Group Co Ltd
SZSE:000538
Net Income (Common)
¥5.2B
CAGR 3-Years
20%
CAGR 5-Years
-1%
CAGR 10-Years
6%
Zhejiang Nhu Co Ltd
SZSE:002001
Net Income (Common)
¥6.8B
CAGR 3-Years
23%
CAGR 5-Years
14%
CAGR 10-Years
33%
S
Sichuan Biokin Pharmaceutical Co Ltd
SSE:688506
Net Income (Common)
¥3.7B
CAGR 3-Years
N/A
CAGR 5-Years
244%
CAGR 10-Years
N/A
No Stocks Found

Tianjin Pharmaceutical Da Ren Tang Group Corp Ltd
Glance View

Market Cap
30.8B CNY
Industry
Pharmaceuticals

Tianjin Pharmaceutical Da Ren Tang Group Corp Ltd, rooted in the rich tapestry of traditional Chinese medicine, has carved out a substantial presence in the pharmaceutical industry. Established in a region known for its deep cultural heritage in holistic healing, the company seamlessly weaves ancient practices with modern scientific advancements. At the core of its operations, Da Ren Tang specializes in the research, development, production, and distribution of traditional Chinese medicine and pharmaceuticals. Beyond just leveraging ancient recipes, the company invests significantly in cutting-edge research to validate and enhance the efficacy of its formulations, gaining trust not only domestically but also in international markets. This blending of tradition and innovation enables Da Ren Tang to capture a diverse customer base, ranging from individuals seeking natural remedies to medical institutions incorporating holistic approaches into patient care. The economic engine of Da Ren Tang powers through a multi-faceted monetization strategy. It manufactures a broad portfolio of pharmaceutical products, including patented Chinese medicines and active pharmaceutical ingredients (APIs), which are distributed through a well-established network of pharmacies and healthcare providers. Additionally, the company has embraced the digital era by exploring e-commerce platforms, thereby expanding its reach and accessibility to tech-savvy consumers globally. By maintaining stringent quality controls and adopting sustainable practices in its production processes, Da Ren Tang not only enhances its reputation but also adheres to evolving regulatory standards worldwide. Such strategic positioning allows the company to capitalize on the growing global interest in traditional medicines, contributing significantly to its revenue streams and reinforcing its status as a prominent player in the pharmaceutical landscape.

Intrinsic Value
37.33 CNY
Overvaluation 7%
Intrinsic Value
Price ¥39.96

See Also

What is Tianjin Pharmaceutical Da Ren Tang Group Corp Ltd's Net Income (Common)?
Net Income (Common)
2.1B CNY

Based on the financial report for Dec 31, 2025, Tianjin Pharmaceutical Da Ren Tang Group Corp Ltd's Net Income (Common) amounts to 2.1B CNY.

What is Tianjin Pharmaceutical Da Ren Tang Group Corp Ltd's Net Income (Common) growth rate?
Net Income (Common) CAGR 10Y
17%

Over the last year, the Net Income (Common) growth was -4%. The average annual Net Income (Common) growth rates for Tianjin Pharmaceutical Da Ren Tang Group Corp Ltd have been 35% over the past three years , 26% over the past five years , and 17% over the past ten years .

Back to Top
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett